|Bid||5.18 x 900|
|Ask||7.25 x 900|
|Day's Range||5.06 - 5.85|
|52 Week Range||1.42 - 12.30|
|Beta (5Y Monthly)||0.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge,.